Finance

Lists
BMYB34:BVMF
Bristol-Myers Squibb Company BDR
331,90 R$
+0,65%
(+2,15) 1D
30 სექ, 11:31:25 GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for BMYB34...
Mkt. cap
120,13 მლრ.
Avg. vol.
10,00
Volume
0,00
52-wk high
347,15 R$
52-wk low
221,72 R$
Shares outstanding
2,04 მლრდ.
No. of employees
32 ათ.
Mkt. cap
120,13 მლრ.
Avg. vol.
10,00
Volume
0,00
52-wk high
347,15 R$
52-wk low
221,72 R$
Shares outstanding
2,04 მლრდ.
No. of employees
32 ათ.
News stories
From web sources and news partners
Profile
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2025, 69% of the company's revenues came from the United States. The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000. Wikipedia
About Bristol-Myers Squibb Company BDR
CEOქრის ბერნერი
Employees32,5 ათ.
Founded1887
Headquartersნიუ-იორკი, ნიუ-იორკის შტატი, ამერიკის შეერთებული შტატები
SectorPharmaceutical industry
Websitebms.com
Last report
30 ივლ. 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
2,04 US$ / 1,60 US$
+27,74%beat
Revenue / Est. (USD)
12,97 მლრდ. / 11,74 მლრდ.
+10,53%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
12,22 მლრდ.
12,50 მლრდ.
11,49 მლრდ.
12,97 მლრდ.
Cost of goods sold
3,31 მლრდ.
3,51 მლრდ.
3,41 მლრდ.
3,71 მლრდ.
Cost of revenue
3,31 მლრდ.
3,51 მლრდ.
3,41 მლრდ.
3,71 მლრდ.
Research and development expenses
2,43 მლრდ.
2,56 მლრდ.
2,24 მლრდ.
2,54 მლრდ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,79 მლრდ.
2,09 მლრდ.
1,61 მლრდ.
1,82 მლრდ.
Operating expense
5,05 მლრდ.
5,47 მლრდ.
4,28 მლრდ.
4,80 მლრდ.
Total operating expenses
8,36 მლრდ.
8,98 მლრდ.
7,69 მლრდ.
8,51 მლრდ.
Operating income
3,86 მლრდ.
3,52 მლრდ.
3,80 მლრდ.
4,46 მლრდ.
Other non operating income
529,00 მლნ.
544,00 მლნ.
125,00 მლნ.
106,00 მლნ.
EBT including unusual items
3,11 მლრდ.
1,47 მლრდ.
3,24 მლრდ.
4,09 მლრდ.
EBT excluding unusual items
4,07 მლრდ.
3,86 მლრდ.
3,65 მლრდ.
4,35 მლრდ.
Income tax expense
919,00 მლნ.
384,00 მლნ.
561,00 მლნ.
770,00 მლნ.
Effective tax rate
29,51%
26,12%
17,32%
18,84%
Other operating expenses
-
-
-
-
Net income
2,20 მლრდ.
1,09 მლრდ.
2,68 მლრდ.
3,32 მლრდ.
Net profit margin
18,01%
8,69%
23,30%
25,57%
Earnings per share
1,63
1,26
1,58
2,04
Interest and investment income
161,00 მლნ.
148,00 მლნ.
104,00 მლნ.
101,00 მლნ.
Interest expense
-482,00 მლნ.
-432,00 მლნ.
-406,00 მლნ.
-403,00 მლნ.
Net interest expenses
-321,00 მლნ.
-284,00 მლნ.
-302,00 მლნ.
-302,00 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
4,91 მლრდ.
4,54 მლრდ.
4,41 მლრდ.
5,08 მლრდ.
Gain or loss from assets sale
-9,00 მლნ.
-
-34,00 მლნ.
-142,00 მლნ.
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები